Status | Study |
Not yet recruiting |
Study Name: Savolitinib vs. Sunitinib in MET-driven PRCC Condition: Carcinoma Carcinoma, Renal Cell Kidney Neoplasms Date: 2017-02-09 Interventions: Drug: Savolitinib 600 mg (400 |
Recruiting |
Study Name: A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma Condition: Renal Cell Carcinoma Clear-cell Renal Cell Carcinoma Date: 2016-07-13 Interventions: Drug: CDX-014 |
Recruiting |
Study Name: Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Condition: Recurrent Renal Cell Carcinoma Stage III Renal Cell Cancer Date: 2016-05-02 Interventions: Drug: Cabozantinib S-malate Gi |
Recruiting |
Study Name: Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma Condition: Renal Cell Carcinoma Hereditary Leiomyomatosis and Renal Cell Cancer Date: 2015-07-08 Interventions: Drug: Vandetanib Vandetanib is |
Recruiting |
Study Name: Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma Condition: Papillary Renal Cell Carcinoma Date: 2015-06-19 Interventions: Drug: axitinib Other Name: Inlyta |
Active, not recruiting |
Study Name: A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) Condition: Papillary Renal Cell Cancer Date: 2014-04-23 Interventions: Drug: AZD6094 AZD6094 is a potent and selective small molecule cMet kinase inhibitor. |
Recruiting |
Study Name: A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer Condition: Papillary Renal Cell Carcinoma Date: 2013-12-20 Interventions: Drug: INC280 Supplied by Novartis as film-coated tablet for oral use. |
Recruiting |
Study Name: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Condition: Carcinoma of the Collecting Ducts of Bellini Chromophobe Renal Cell Carcinoma Date: 2013-01-10 Interventions: Drug: Pazopanib Hydrochloride Given PO Other Names: |
Active, not recruiting |
Study Name: Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer Condition: Clear Cell Renal Cell Carcinoma Recurrent Renal Cell Carcinoma Date: 2012-11-12 Interventions: Biological: Anti-Endoglin Chimeric Monoclonal Antibody TRC105 |
Active, not recruiting |
Study Name: Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery Condition: Recurrent Renal Cell Carcinoma Stage III Renal Cell Cancer Date: 2012-09-14 Interventions: Drug: Erlotinib Hydrochloride |